Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HMBD-001 + docetaxel
- Development stage
- Phase 2
- Lead developer
- Hummingbird Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HMBD-001 + docetaxel is a combination investigational therapy composed of HMBD-001, a humanized IgG1 monoclonal antibody targeting HER3 (ERBB-3), and docetaxel, a chemotherapeutic agent of the taxane class. HMBD-001 binds to a unique epitope at the domain II dimerization interface of HER3, effectively blocking EGFR/HER2-HER3 heterodimerization and potently inhibiting PI3K signaling, irrespective of ligand binding to the receptor. This mechanism prevents HER3-driven tumor growth and drug resistance. Docetaxel stabilizes microtubules, preventing cell division and inducing apoptosis in proliferating cancer cells. The combination is being explored in solid tumors, particularly those with HER3 signaling aberrations such as NRG1 fusions or HER3 mutations, including squamous cell carcinoma and other HER3-driven cancers in advanced/metastatic settings.
- Other names
- HMBD-001HMBD001HMBD 001
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HMBD-001 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HMBD-001 + docetaxel.